PCSK9 Forum
Click here to invite colleagues
to join the Forum for FREE
Facebook Twitter RSS YouTube linkedin
Home  |  About  |  PCSK9  |  News  |  Commentary  |  Trials  |  Videos  |  Resources  |  Contact
Hot Off the Press
What is value of addressing unmet needs in high risk CV patients?
The debate hots up

Given the proven ability of PCSK9 inhibitors to lower LDL-cholesterol beyond other agents - alone or in combination - the debate has focused on strategies to define in whom these new agents should be used.

Contributing to the discussion, the Institute for Clinical and Economic Review (ICER) has performed a medico-economic evaluation in high risk patients.

The number of patients needed to treat (NNT) in different patient settings are summarised.

Summary of key outcomes from the analysis

Target patient population Estimated patient group NNT over
5 years*
QALY gained
Familial hypercholesterolaemia 6% 28 $290,000
History of CVD and statin intolerant 17% 21 $274,000
History of CVD and inadequate LDL-C lowering on statin** 78% 21 $302,000

*To prevent one myocardial infarction over 5 years;
**based on a target LDL cholesterol <70 mg/dl or 1.8 mmol/L; CVD cardiovascular disease; LDL-C low-density lipoprotein cholesterol; QALY quality-adjusted life-year

The implications of the report are discussed here »

Read full report »

Forward to colleagues »

Tice JA, Kazi DS, Pearson SD. Proprotein Convertase Subtilisin/Kexin Type 9 (PSCK9) inhibitors for treatment of high cholesterol levels. Effectiveness and value. JAMA Intern Med. Published online December 14, 2015. Doi:10.1001/jamainternmed.2015.7248.

Study questions PCSK9 in ACS patients

Elevated PCSK9 levels are not predictive of 1-year mortality in patients with Acute Coronary Syndrome (ACS).

Read full report »

New lectures online
Insights from Forum experts

Innovative PCSK9 - targeted therapeutics - siRNA

    Professor Stephen Nicholls

South Australian Health and Medical Research Institute, Australia

View slides »

Monoclonal Antibodies: New options for diagnosis and therapy

Professor Dario Neri

Department of Chemistry and Applied Biosciences, Institute of Pharmaceutical Sciences, Switzerland

View slides »
Click here to invite colleagues to join FREE
Why are new treatments needed?

Millions of people who suffer with hypercholesterolaemia remain at a high risk of premature death, despite current treatment.

Read the full answer and other questions on the PCSK9 Forum »
Free e-book
Understanding PCSK9 inhibition
For healthcare professionals

Prepared by independent experts from PCSK9 Education and Research Forum.

Available free.

Register and read online »    Download now »
PCSK9 Inhibition Handbook
Like us on Facebook
For the latest updates on conferences, PCSK9 news and video reports.
Follow us on Twitter
For updates on hot topics,
PCSK9 news and conference reports.
YouTube Channel
For the latest videos, interviews and webcasts from leading experts.
Educational Partners
and Supporters
Amgen Lilly The Medicines Company pFizer Sanofi
Copyright PCSK9 Forum 2016. Please click here to unsubscribe from future mailings.